Thyrotropin-releasing hormone (TRH), a hypothalamic tripeptide, is expressed in pancreatic islets at peak levels during the late gestation and early neonate period. TRH increases insulin production in cultured -cells, suggesting that it might play a role in regulating pancreatic -cell function. However, there is limited information on TRH receptor expression in the pancreas. The aim of the present study was to explore the distribution of the TRH receptor in the pancreas and its function in pancreatic -cells. TRH receptor type 1 (TRHR1) gene expression was detected by RT-PCR and verified by Northern blotting and immunoblotting in the -cell lines, INS-1 and TC-6, and the rat pancreatic organ. The absence of TRH receptor type 2 expression in the tissue and cells indicated the tissue specificity of TRH receptor expression in the pancreas. The TRHR1 signals (detected by in situ hybridization) were distributed not only in islets but also in the surrounding areas of the pancreatic ductal and vasal epithelia. The apparent dissociation constant value for the affinity of [ 3 H]3-methyl-histidine TRH (MeTRH) is 4·19 in INS-1 and 3·09 nM in TC-6. In addition, TRH induced epidermal growth factor (EGF) receptor phosphorylation with a half-maximum concentration of approximately 50 nM, whereas the high affinity analogue of TRH, MeTRH, was 1 nM. This suggested that the affinity of TRH ligands for the TRH receptor influences the activation of EGF receptor phosphorylation in TC-6 cells. Our observations suggested that the biological role of TRH in pancreatic -cells is via the activation of TRHR1. Further research is required to identify the role of TRHR1 in the pancreas aside from the islets.
Introduction
Thyrotropin-releasing hormone (TRH), originally characterized and extensively studied as a hypothalamic tripeptide, plays a key role in the regulation of the thyroid axis (Hajjar et al. 1973 , Azizi et al. 1974 , Jackson et al. 1974a ,b, Martino et al. 1978 . In addition to the hypothalamus, TRH has been identified in many systemic organs including the pancreas (Martino et al. 1978 , Koivusalco & Leppaluoto 1979 , Morley et al. 1979 , Engler et al. 1982 , Aratan-Spire et al. 1984 , Leduque et al. 1985 , Fuse et al. 1990 ). In the pancreas, TRH expression is at its peak during the neonatal period and gradually declines after birth (Martino et al. 1978 , Basmaciogullari et al. 2000 . The distribution of TRH in the pancreas has been localized in both the islet -cells and other pancreatic cells (Basmaciogullari et al. 2000) . TRH promotes insulin release from adult islets (Kulkarni et al. 1995) and TRH gene knockout induces mild hyperglycemia (Yamada et al. 1997) , suggesting that the expression of TRH in the pancreas might be involved in the regulation of pancreatic -cell function. TRH-induced transactivation of the epidermal growth factor (EGF) receptor in an immortalized -cell line (Luo et al. 2002) implies that TRH might influence -cell differentiation and development through cross-talk with a growth factor receptor. Two subtypes of TRH cognate receptors have been identified. TRH receptor type 1 (TRHR1) was originally cloned in 1990 using expression cloning in Xenopus laevis (Straub et al. 1990 ) and TRH receptor type 2 (TRHR2), which was identified in 1998 by two groups simultaneously (Cao et al. 1998 , Itadani et al. 1998 . Although TRHR1 and 2 share no more than 68% homology of their amino acid sequence, there are no significant differences in binding or in acute stimulation of signaling between the subtypes (O'Dowd et al. 2000 , Sun et al. 2003 .
The distribution of TRHR2 in brain tissues is more extensive than that of TRHR1 (Sun et al. 2003 ) and TRHR2 localization is strictly limited in the central nervous system (CNS). TRHR2 is more rapidly bound to TRH and has a greater level of TRH-induced downregulation than TRHR1 (O'Dowd et al. 2000) . All the findings suggest that TRHR2 mediates many of the known functions of TRH that are not transduced by TRHR1 in the CNS (O'Dowd et al. 2000) . In contrast to TRHR2, TRHR1 is widely distributed in several peripheral tissues (Leduque et al. 1989 , Satoh et al. 1993 , 1994 , Yamada et al. 2000 . The tissue-specific diversity of the systematic distribution of TRHR1 and TRHR2 accounts for the various biological roles of TRH in peripheral tissues separate from the CNS and possibly by the autocrine or paracrine cells.
Although TRH expression has been observed in the pancreatic islet, only one report has identified the expression of the TRH receptor in the -cell line and islet (Yamada et al. 2000) . In the present study, we have identified the distribution of the TRH receptor in the rat pancreas and its expressions in the immortalized -cell lines, INS-1 and TC-6. The affinity of the expressed TRHR1 was evaluated by binding assay. The biological functions of TRH on insulin production and EGF receptor phosphorylation were determined in the -cell lines.
Materials and Methods

Cell culture
Unless stated otherwise, media, supplements and all other materials used for cell culture were obtained from Invitrogen (Carlsbad, CA, USA).
Mouse pancreatic -cell line, TC-6, was provided by the American Type Culture Collection (Manassas, VA, USA). Rat cell line INS-1 was a gift from Dr Claes Wollheim (Centre Médical Universitaire, Geneva, Switzerland). TC-6 cells were grown in Dulbecco's modified Eagle's medium supplemented with 15% fetal bovine serum (FBS). INS-1 cells were cultured in RPMI-1640 with 10% FBS and 50 µM 2-mercaptoethanol to maintain differentiation. Semi-confluent (80-90%) monolayer cells in 100 mm polystyrene dishes (Becton Dickinson, Lincoln Park, NJ, USA) and 15-40 cell passages were used for the experiments.
RT-PCR and PCR direct sequencing
Total RNA was isolated from cells using TRIzol Reagent (Invitrogen). As described previously (Yano et al. 1997) , cDNA was generated from 5 µg of the total RNA by reverse transcription. cDNA was subject to 30 cycles of PCR using the following primers: TRHR1 sense (rat), 5 -GCC CTC GAG TAC CAG GTG GTC ACC ATC-3 ; TRHR1 antisense (rat), 5 -AGT AGT AGT TGC GGG AGA TCT TGT AGC CA-3 ; TRHR1 sense (mouse), 5 -GCC CTC GAG TAC CAG GTG GTT ACC ATC-3 ; TRHR1 antisense (mouse), 5 -AGT AGT AGT TCC TGG AGA TCT TGT AGC CA-3 ; TRHR2 sense (rat), 5 -ATC AAT GTC TCC TCC TTC TCC ATC C-3 ; TRHR2 antisense (rat), 5 -GAC AAC GGG CTC TGA AAT AAA ATC C-3 ; TRHR2 sense (mouse), 5 -ATC AAT GTC TCC TCC TGC TCC ATC C-3 ; TRHR2 antisense (mouse), 5 -GAC AAT GGG CTC TGA AAT AAG ATC C-3 . Each cycle consisted of 1 min at 94 C, 2 min at 65 C and 2 min at 72 C. The PCR product was run on 2% agarose gel, stained with ethidium bromide and then photographed. For sequencing analysis, the band from the PCR product was extracted and reconstituted in Tris-EDTA buffer after being run on 1% agarose gel and directly analyzed by the Taq DNA polymerase cycle sequence method as described previously (Yano et al. 1998) . The sense primer that was used for RT-PCR was used as a primer for the sequencing. Each sequencing cycle consisted of 15 s at 94 C, 45 s at 64 C and 60 s at 70 C. After 30 cycles of the reaction, alkaline heat-denatured samples were loaded onto sequencing gel. Analysis was performed using an automated DNA sequencer (model ABI PRISM 377; Perkin-Elmer, Foster City, CA, USA) at the Brown University Automated DNA Sequencing Facility. By manipulating the RT-PCR procedure, it was found that lowering Mg 2+ concentrations in the PCR reaction down to 5 mM generated a consistent PCR product. The product generated from this method for sequence analysis also proved consistent for TRHR1.
Northern blotting
Preparation of TRHR1 probe The University of Iowa (UI) rat EST clone including fragments of the TRHR1 sequence in pT7T3D-Pac vector (UI-R-B00-agm-g-01-0-UI) was purchased from Invitrogen. The clone was seeded on an LB agar plate and a single colony that grew on the plate was picked up and its insert was amplified by PCR using universal PCR primers. The sequences of the primers were as follows: T7-95 upper primer, 5 -TTA ATA CGA CTC ACT ATA GGG -3 and T3-94 lower primer, 5 -AAT TAA CCC TCA ATA AAG GG-3 .
The PCR product from the EST clone was purified by running on agarose gel and extraction. The probe was generated by labeling the purified PCR product with dCTP [ -32 P] (ICN Pharmaceutical, Inc., Bryan, OH, USA) using random primers DNA labeling systems (Invitrogen).
Hybridization Isolated RNA from each sample (10 µg) was run on 1% agarose gel in 1 MOPS and 2·2 M formaldehyde, and then transferred to positively charged nylon membrane (Immobilon-Ny + ; Millipore, Billerica, MA, USA). After the transfer, RNA on the membrane was immobilized using an automated u.v. cross-linker (Stratagene, La Jolla, CA, USA) and hybridized with dCTP -32 P-labeled probe in 50% formamide hybridization buffer for 16 h at 65 C with continuous rotation. After the hybridization, the membranes were washed four times under highly stringent conditions and exposed to BioMax MS high-sensitivity film (Eastman Kodak Co., Rochester, NY, USA).
In situ hybridization
Fresh frozen rat pancreas was cut into 5 µm slices and mounted on glass slides that were immediately fixed in 4% paraformaldehyde in phosphate-buffered saline (PBS) then dehydrated with ethanol. A PCR DIG probe synthesis kit (Roche Diagnostic, Indianapolis, IN, USA) was used to generate a digoxigenin guanosine 5 -tri-phosphate-labeled PCR probe and labeled probe was verified by dot blotting. For prehybridization, the slides were incubated with 50% formamide and 10 Denhardt's solution at 42 C for 2 h. Hybridization was performed with a denatured TRH receptor digoxigenin-labeled probe at 20 ng in 50% formamide and 10 Denhardt's solution containing 50 mg/ml tRNA and 10 mg/ml denatured sperm DNA was incubated at 42 C for 16 h. After hybridization, the slides were washed with 50% formamide in 2 SSC for 20 min, 1 SSC for 15 min at room temperature and then treated with RNase A (20 µg/ml in RNase buffer) for 10 min at 37 C and washing with 1 SSC twice for 5 min each. The slides were exposed to 200 µg/ml digoxigenin-alkaline phosphatase-fluorescein (Boehringer Mannheim, Indianapolis, IN, USA) in 1% PBS blocking solution, incubated for 30 min at 37 C and washed twice with PBS solution for 5 min each time. After hybridization, immunohistochemistry was performed on the same slide. The slide was blocked with 3% normal goat serum for 20 min and incubated with mouse anti-insulin monoclonal antibody (CHEMICON, Temecula, CA, USA) for 2 h at room temperature. After being washed three times, the slide was incubated with anti-mouse biotin conjunction second antibody (1:50) for 20 min, washed five times and Avidin-Texas red (1:100; Vector Laboratories Inc., Burlingame, CA, USA) was added for 10 min at 37 C. After washing with PBS with 5% Tween 20 five times, the slides were covered with Vectashield Dapi in mounting medium (Vector Laboratories, Inc., Burlingame, CA, USA) for nucleus staining and examined under a microscope with filter excitation at 494 nm and emission at 523 nm. Controls included slides hybridized in the absence of either the digoxigenin-labeled probe or the AP-conjugated antibody. Background labeling was observed when hybridization was conducted with the corresponding sense probes. A slide from a series of sections in the same sample stained with hematoxylin and eosin (HE) was assessed for histological structure (Luo et al. 1995 , Luo & Jackson 1998 .
Immunoprecipitation
Cell lysates were mixed with agarose-conjugated antibody and incubated overnight at 4 C with gentle rotation. The lysate-antibody mixture was washed three times with RIPA buffer (20 mM Tris-HCl, pH 7·4, 0·1% SDS, 1% Triton X-100 and 1% sodium deoxycholate). After removing the washing buffer, the sediment was resuspended with 50 ml 2 SDS protein sample buffer then vortexed vigorously. After being left at room temperature for 40 min, the mixtures were centrifuged at 1500 g for 5 min and all the supernatants were processed for immunoblotting as described in the following section on Western blotting.
Western blotting
Cells or tissue homogenates were lysed in lysis buffer containing phosphatase inhibitors (50 mM Tris-HCl, pH 7·5, 0·2% Sigma phosphatase inhibitor cocktail II (Sigma) and 0·1% Nonidet P-40) and shaken on ice for 2 h. After being centrifuged at 10 000 g for 30 min at 4 C, the supernatant was collected and the protein content of all samples was determined with a spectrophotometric protein assay kit (Pierce, Rockford, IL, USA). An identical amount of protein (usually 50 µg/lane) was subjected to polyacrylamide mini gels. After transfer, nitrocellulose membranes were blocked in a solution of 5% milk and 0·5% Tween 20 in Tris-buffered saline for 2 h and incubated with specific antibodies overnight at 4 C followed by HRP-conjugated second antibody. After washing, protein bands were identified by enhanced chemiluminescence (Super Signal; Pierce) and BioMax MS high sensitive X-ray film (Eastman Kodak Co.) (Luo et al. 1999) .
Binding assay
The TRH-binding assay was performed in 12-well plates (10 6 cells/well) after 2 days of cell culture. The binding was carried out in a 0·5 ml volume of medium (Hank's balanced salt solution and 10 mM HEPES, pH 7·4) containing various concentrations of MeTRH (Sigma) a high affinity analogue of TRH, from 0·001 to 50 nM with a total of 12 concentration points at 4 C for 6 h. To evaluate non-specific binding, 500-to 1000-fold excess unlabeled MeTRH was added to parallel wells in addition to MeTRH. After the binding reaction at room temperature for 1 h, cells were washed twice with cold assay medium and dissolved in 0·4 M NaOH, and the radioactivity was calculated by subtracting the non-specific binding from MeTRH binding in the absence of unlabeled MeTRH. The saturation plot was analyzed by Sigma Plot program (SPSS Inc., Chicago, IL, USA).
Insulin ELISA
INS-1 and -TC6 cells at 5 10 5 cells/well were incubated in 24-well culture plates. After incubation with serum-free medium overnight, the cells were incubated with or without 200 nM TRH for 24 h in insulin-free medium. After the incubation, culture media were collected and cell contents were extracted from scraped-off cells with 5% trichloracetic acid (TCA) then neutralized with 4 M Tris buffer. Six controls and six TRH-treated cells were tested separately in each group. Insulin concentrations were measured using an ultrasensitive rat insulin ELISA kit (Crystal Chem Inc., Downer Grove, IL, USA) according to the manufacturer's instructions. Briefly, insulin standards and appropriately diluted (1:50-1:500) cell extracts and media were added to insulin antibodycoated 96-well microplates and incubated for 2 h at 4 C. After washing five times, anti-rat insulin enzyme conjugate was added to the well and incubated for 30 min at room temperature. After washing seven times, enzyme substrate solution was added, then incubated for up to 45 min at room temperature in the dark. The reaction was stopped by adding 1 M sulfuric acid. Absorbance at 450 nm was read with a µQuant microplate reader (Bio-Tek Instruments, Inc., Winooski, VT, USA) and concentrations were calculated by KC Junior microplate reader software (Bio-Tek Instruments, Inc.).
Image analysis
Data are shown as means S.D. Densitometric analysis of the blotting image was carried out using Scion Image for Windows (Scion Corp., Frederick, MD, USA). All the graphs from the image data and statistical evaluation (Student's t-test) were performed using MS Excel (Microsoft, Redmond, WA, USA) and Sigma Plot software.
Results
Expression of TRHR1 mRNA in -cell lines and rat pancreas
The single distinct band (503 bp) of TRHR1 mRNA in INS-1, -TC6 and rat pancreas was detected by RT-PCR (Fig. 1A) . Direct DNA sequencing from the PCR product completely matched a TRHR1 sequence from the GenBank database (Fig. 1B ). There were no significant amplifications of TRHR2 mRNA in the cells and pancreas, although an apparent amplification was detected in the hypothalamus (data not shown). Northern blotting further confirmed a distinct signal of TRHR1 in rat pancreas, INS-1 and TC-6 cells (Fig. 2) . With double labeling of non-isotopic in situ hybridization and insulin immunohistochemistry performed in rat pancreatic slides and HE histological staining for pancreatic structure, the distribution of signals for TRHR1 expression were found to be localized within insulin-stained cells in islets, ductal and vasal epithelia in the pancreas; indicating that the TRH receptor is expressed in both -cells in islets and the areas outside of islets (Fig. 3) .
Protein expression of TRHR-1 in pancreas
The presence of TRHR 1 in -cell lines as well as in the pancreas was confirmed by receptor protein level.
Immunoblotting with TRHR1-specific rabbit polyclonal antibody (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) was applied to detect TRHR1 protein with a positive control, the pituitary. Figure 4 indicates that the TRHR1 protein was expressed in both -cell lines and the pancreas. A stronger expression at the expected size (approximately 40 kDa) in the pituitary served as a positive control.
Affinity of TRH receptor in INS-1 and TC-6 cells
Further functional tests were performed by the binding affinity of TRHR1 with a receptor radiolabeled-binding assay in INS-1 and TC-6 cells. As shown in Fig. 5 , the 
Increase in insulin contents and secretion in -cell lines with TRH treatment
Insulin levels in cell extracts from -TC6 and INS-1 were measured to evaluate the effects of TRH on insulin production and secretion. TRH significantly enhanced insulin production in cell extracts ( 
Activation of EGF receptor phosphorylation by TRH and MeTRH
For further testing of the biological function of TRH in pancreatic -cells, EGF receptor phosphorylation in response to TRH was detected by Western blotting (Luo et al. 2002) . MeTRH, a high affinity TRH analogue to the TRH receptor, is about tenfold the binding ability of native TRH. The activity of TRH and its analogue on EGF receptor phosphorylation in TC-6 cells was examined with various concentrations of TRH (from 50 to 500 nM) and MeTRH (from 0·1 to 50 nM). The cell lysates were immunoprecipitated with agarose-conjugated phosphorylated tyrosine specific antibody (PY20; Santa Cruz Biotechnology, Inc.) and immunoblotted with anti-EGF receptor antibody (SC1005; Santa Cruz 
Figure 6
Insulin ELISA for TC-6 and INS-1 cell extracts and medium. Cells were cultured for 24 h with or without TRH (n=6 in each group). Culture medium was collected and harvested and cells were extracted by 5% TCA. Insulin contents and secretion were measured by ELISA. Insulin contents in cells were normalized with protein concentration (mg/ml) of the extracts. TRH-treated cells contained higher amount of insulin than controls in (A) cell extracts and (B) culture medium. *P<0·01 vs control ( TC-6), **P<0·01 vs control (INS-1).
Discussion
The pancreatic organ or cell lines are known to show similarity in the developmental process or gene expression patterns, which are found in neurons and possess variable neuronal derivative peptides and hormones (Wolff et al. 1996 , Emanuel et al. 2000 , Lumelsky et al. 2001 . The expressions of TRH (Koivusalco & Leppaluoto 1979) and its biological effects on pancreatic -cells and pancreas have been reported (Kulkarni et al. 1979 , Glasbrenner et al. 1990 , Yamada et al. 2000 . In the present study, TRH enhanced insulin production in cultured -cell lines, which indicated that TRH directly affects pancreatic -cells. However, in spite of the suggestive findings, the biological role and mechanisms of endogenous TRH directly upon the pancreas have not been fully elucidated.
There are two types of TRH receptors (TRHR1 and TRHR2) which have been identified previously (Straub et al. 1990 , Cao et al. 1998 , Itadani et al. 1998 . More recently, a third subtype of the receptor (TRHR3) has been cloned from Xenopus laevis (Bidaud et al. 2002) . TRHR3 is distributed similarly to TRHR2 in the CNS. However, due to an extremely low affinity of the new molecule to TRH in comparison with TRHR1 and 2, the novel receptor has not been determined to be a true cognate ligand of TRH . TRHR1 is widely distributed in the CNS and extends to several peripheral organs (Calzá et al. 1992 , Satoh et al. 1993 , 1994 , Zabavnik et al. 1993 , Wolff et al. 1996 compared with TRHR2. Therefore, the putative biological function of TRH in peripheral organs, including the effects of TRH on pancreatic cells, is probably mediated by TRHR1.
In the present study, we have demonstrated the transcription and translation of TRHR1 in an immortalized -cell line and rat pancreas. It is the first report to find strong TRH receptor expression not only in the islet but also in the ductal and epithelial cells surrounding the endocrine cells in the pancreas, which could explain the findings that mRNA expression from the entire pancreas in Northern blotting is stronger than that in -cell lines (Fig. 2) . The physiological significance of the wide distribution of TRHR1 in the pancreas needs to be further explored. The affinity of the expressed TRHR1 has been verified by receptor binding analysis and the results revealed that the TRH receptor in an immortalized -cell line possesses modest affinity (K d values for INS-1 and TC-6 were 4·19 and 3·09 nM respectively). The affinities were generated from 12 different concentrations with a maximum of 50 nM [ 3 H]MeTRH, which was fivefold higher than the maximum binding concentration (10 nM).
The affinity value calculated from these ranges of concentrations was consistent with other studies (Yamada et al. 2000) . TRH increased the -cell insulin production and secretion during the 24 h of incubation, which indicated that TRH and its receptors play an important role in the prolonged regulation of -cell function. The previous findings showed that TRH is a candidate in the activation of the phosphorylation of EGF receptor in -cells through its cognate receptor and Src kinase-related signal transduction pathway (Luo et al. 2002) . This finding prompted us to test whether different affinity analogues of TRH may produce various responses from the EGF receptor. TRH and its analogue, MeTRH, activated phosphorylation of EGF receptor in a dose-response fashion in TC-6 cells and MeTRH was more potent in phosphorylating the EGF receptor than native TRH. That the biological effect of TRH could be mediated through TRHR1 and that the receptors on TC-6 cells maintain intact functions indirectly support this. The EGF receptor, in response to MeTRH, had a more than tenfold potent affinity than that of native TRH, which might imply that there are amplificatory pathways between TRH receptor and EGF receptor. Once the higher affinity of MeTRH activates the TRH receptor, the signal might be amplified by multiple signal transduction pathways (Luo et al. 2003) to the end EGF receptor activation.
Since TRH does not directly bind to EGF receptor (Luo et al. 2003) , the signal transduction amplificatory effect might explain why EGF receptor transactivation has a relevant action of G protein-coupled receptors linked to Ras/MAP kinase activation (Daub et al. 1996) and protein synthesis (Voisin et al. 2002) . Although the specific effects of EGF on insulin synthesis have not been identified, TRH activation of EGF receptor phosphorylation influencing the relative pathways cannot be excluded.
The demonstration of TRH receptor expression and function in pancreatic tissue is as important as elucidating the mechanism of TRH function in the CNS. The presence of both the tripeptide and its receptor in the pancreas suggests that TRH has a specific biological role in these tissues and effects do not occur by a non-specific receptor mechanism.
In conclusion, we have verified the expression of TRHR1 in pancreatic -cell lines and rat pancreatic tissue. The expression of TRH and its receptor in pancreatic tissue suggests that TRH might play a biological role in pancreatic cells in an autocrine or paracrine fashion. Further studies are required in order to elucidate the physiological significance of TRHR1 in the various cell types found in the pancreas and the role of TRH in pancreatic development. for his valuable suggestions and John Z Q Luo for assistance in editing the paper and clarifying the images. This work was presented at the 63rd American Diabetes Association Annual Meeting in New Orleans, LA, USA on 13-17 June 2003.
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